Mutual of America Capital Management LLC Purchases New Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Mutual of America Capital Management LLC purchased a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 35,056 shares of the biotechnology company's stock, valued at approximately $701,000.

Other large investors have also modified their holdings of the company. Natixis Advisors LLC purchased a new stake in shares of ADMA Biologics during the third quarter valued at $345,000. Oppenheimer & Co. Inc. lifted its position in ADMA Biologics by 85.8% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 94,938 shares of the biotechnology company's stock worth $1,898,000 after acquiring an additional 43,836 shares during the period. Aigen Investment Management LP purchased a new stake in ADMA Biologics during the 3rd quarter valued at about $583,000. Entropy Technologies LP acquired a new position in shares of ADMA Biologics in the third quarter valued at about $757,000. Finally, Lisanti Capital Growth LLC purchased a new position in shares of ADMA Biologics in the third quarter worth about $4,698,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. Raymond James upped their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a report on Friday, November 8th. Finally, HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th.

ADMA Biologics Stock Performance

ADMA traded up $0.01 on Wednesday, reaching $21.83. The stock had a trading volume of 1,940,312 shares, compared to its average volume of 3,621,177. ADMA Biologics, Inc. has a 12-month low of $3.60 and a 12-month high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company has a market cap of $5.16 billion, a P/E ratio of 77.96 and a beta of 0.64. The business's 50-day moving average price is $19.03 and its two-hundred day moving average price is $15.19.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. During the same period in the previous year, the firm posted $0.01 EPS. Sell-side analysts forecast that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, Director Jerrold B. Grossman sold 136,861 shares of the company's stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $17.27, for a total value of $2,363,589.47. Following the completion of the transaction, the director now owns 467,305 shares in the company, valued at $8,070,357.35. This represents a 22.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Brad L. Tade sold 15,000 shares of the firm's stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 185,011 shares of company stock worth $3,255,204. 3.70% of the stock is currently owned by company insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.